Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.
about
AKT-ions with a TWIST between EMT and METAberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.Expression of Rab1A is upregulated in human lung cancer and associated with tumor size and T stage.Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.The pharmacogenomics of drug resistance to protein kinase inhibitors.Differentially Expressed lncRNAs in Gastric Cancer Patients: A Potential Biomarker for Gastric Cancer Prognosis.Establishment and characterization of human osteosarcoma cells resistant to pyropheophorbide-α methyl ester-mediated photodynamic therapy.mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.The ectodomain of cadherin-11 binds to erbB2 and stimulates Akt phosphorylation to promote cranial neural crest cell migration.Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells.Autophagy mediates glucose starvation-induced glioblastoma cell quiescence and chemoresistance through coordinating cell metabolism, cell cycle, and survival.Identification and validation a TGF-β-associated long non-coding RNA of head and neck squamous cell carcinoma by bioinformatics method.Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival.Whole exome sequencing identifies mTOR and KEAP1 as potential targets for radiosensitization of HNSCC cells refractory to EGFR and β1 integrin inhibition.The Roles of Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 in Cancer and Cancer Stem Cells.
P2860
Q28078987-E69B3AC0-4919-4C88-A3B7-652C3850BD7DQ33873317-4980AF21-CB63-43D8-BF49-83C30A1F02BBQ37538205-B41DD9DF-CB50-440B-8AAF-08FD4186A019Q37573748-27E9300B-5874-4CD5-9D98-7CFCB1DD0546Q38918710-60D0E0D0-0BAE-4001-856B-7A6B06846852Q38952751-CDB70C35-CD65-4CE5-BAF1-A9E3FCA2F2C6Q41242612-BA0F951B-8899-4333-8E59-3B2C44488461Q42378303-0B18FC38-44F4-4D7D-80BA-B05C11D08BA2Q42378326-4A94284C-87FC-48DB-B0BB-09B0993A908AQ47110810-F19609BC-4126-41E2-A5BE-30381F5750D5Q47161792-C4B9C978-C205-487E-9F32-55F284419827Q47344966-2AB08B3C-58E7-4B42-B76A-25575105F374Q49382862-1735143E-1D26-4D3C-8A06-818CA4C430B0Q50055579-F12FB3FF-E9A0-419B-9176-DABAFDDC2AABQ52680995-297FDFA3-F72F-42E3-A10B-D1F65DC65A0BQ52713189-34D1FEBA-5B52-4359-9BF4-E79DA9D5E74AQ53688963-0CB6100A-7EAE-45E2-825D-09A425DC6EECQ55004493-0CF196D7-20A8-4DA0-9B05-FB97A710ABDC
P2860
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.
@en
type
label
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.
@en
prefLabel
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.
@en
P2093
P2860
P1476
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.
@en
P2093
Brian A Hemmings
Daniela Massi
Daniela Taverna
Gongda Xue
Huifang Tang
Mario Mandalà
P2860
P304
P356
10.1152/PHYSREV.00024.2015
P577
2016-07-01T00:00:00Z